These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 999240

  • 1. [Cross resistance in tumor cells and staphylococci with respect to anthracycline-group antineoplastic antibiotics].
    Shorin VA, Averbukh LA.
    Antibiotiki; 1976 Oct; 21(10):914-9. PubMed ID: 999240
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Development of bruneomycin and rubomycin resistance in mouse lymphadenosis tumor cells and Staphyloccus when these preparations are used separately or together].
    Averbukh LA.
    Antibiotiki; 1977 Dec; 22(12):1103-11. PubMed ID: 596856
    [Abstract] [Full Text] [Related]

  • 4. [Effect of the anthracycline group antibiotics, mitomycin C and bruneomycin, on the transduction of drug resistance in staphylococci].
    Ponomareva TR, Smolianskaia AZ.
    Antibiotiki; 1978 Oct; 23(10):896-902. PubMed ID: 152092
    [Abstract] [Full Text] [Related]

  • 5. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N.
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T.
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [Abstract] [Full Text] [Related]

  • 12. [Comparative cytogenetic action of the antitumor antibiotics, carminomycin and rubomycin].
    Kurlov OV, Koĭfman EK, Gol'dberg ED.
    Antibiotiki; 1978 Jun; 23(6):537-40. PubMed ID: 677842
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Action of carminomycin on the kinetics of cell proliferation and some problems of its combined use with other cytostatic agents].
    Egorov LV, Khanykova OK, Kuznetsova TV, Gerasimova NA, Kozinets GI.
    Antibiotiki; 1977 Jul; 22(7):639-43. PubMed ID: 883808
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Liver mono-oxygenases and the pharmacodynamics of carminomycin and rubomycin].
    Bogush TA, Sitdikova SM.
    Antibiotiki; 1984 Jun; 29(6):446-50. PubMed ID: 6476808
    [Abstract] [Full Text] [Related]

  • 18. [Toxicity and cumulative properties of carminomycin, rubomycin and adriamycin at different times of use].
    Lichinitser MR, Syrkin AB.
    Antibiotiki; 1976 Nov; 21(11):1030-2. PubMed ID: 1020931
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS, Myers MT, Sartorelli AC.
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.